Facing pressing questions about its latest clinical trial in Alzheimer’s disease, Biogen may have sowed further doubt on the future of an investigational treatment on Thursday.

At a medical conference in Spain, Biogen and partner Eisai presented data on the drug, BAN2401, meant to clear up concerns that its earlier observed benefits were a mirage. But the explanation revealed that BAN2401’s glimmer of promise is based on results from a small subset of patients in an otherwise large trial, which could be difficult to replicate in later studies.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • This is typical of the “innovative” deceptive science they are all doing now. These truncated distorted studies, get the attention of industry “journalists” who are indistinguishable from marketers. A few Industry publications will hype these “findings’ and get plenty of funding, and even taxpayer dollars from our government agencies. Depending on where this is advertised, using deceptive marketing, advertorials, and misleading alternate facts, this will be profitable. It may waste billions of research dollars, but a few clever people will make a whole lot of money. They have been misleading us about all of the previous research, and kept getting government grants to “study” clearly useless drugs, because it was profitable. In the meantime real people have to deal with these disorders, day in and out. Most Americans will find that these disorders are misdiagnosed, and their families, livelihoods, and lives will be negatively impacted. The interventions are mostly lies, with most Physicians unable or unwilling to even diagnosed these disorders before lives are ruined.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy